{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:15:31Z","timestamp":1791191731596,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ejca.2011.01.016","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T09:10:57Z","timestamp":1299316257000},"page":"1006-1012","source":"Crossref","is-referenced-by-count":83,"title":["Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"2007-000035-25","registry":"10.18810\/euctr"},{"clinical-trial-number":"2007-000794-31","registry":"10.18810\/euctr"},{"clinical-trial-number":"2007-006681-15","registry":"10.18810\/euctr"},{"clinical-trial-number":"2008-002326-11","registry":"10.18810\/euctr"},{"clinical-trial-number":"2008-008922-55","registry":"10.18810\/euctr"}],"author":[{"given":"P.","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sanfilipio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Le","family":"Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Tercero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.01.016_b0005","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","article-title":"Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata","volume":"55","author":"Rinerhart","year":"1990","journal-title":"J Org Chem"},{"key":"10.1016\/j.ejca.2011.01.016_b0010","unstructured":"European Medicines Agency. Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medical Products for human use. Summary of positive Opinion for Yondelis. Doc. Ref. EMEA\/CHMP\/316962\/2007. London, 19 July 2007."},{"issue":"1","key":"10.1016\/j.ejca.2011.01.016_b0015","first-page":"109","article-title":"Trabectedin and its potential in the treatment of soft tissue sarcoma","volume":"4","author":"Cassier","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.ejca.2011.01.016_b0020","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14656566.9.9.1609","article-title":"Clinical impact of trabectedin (ecteinascidin-743) in advanced\/metastatic soft tissue sarcoma","volume":"9","author":"Sch\u00f6ffski","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejca.2011.01.016_b0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001433-200312000-00011","article-title":"Therapeutic impact of ET-743 (Yondelis\u00ae, Trabectidin) a new marine derived compound in Sarcoma","volume":"14","author":"Jimeno","year":"2003","journal-title":"Curr Opin Orthop"},{"issue":"3","key":"10.1016\/j.ejca.2011.01.016_b0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1634\/theoncologist.7-3-210","article-title":"Unique features of the mode of action of ET-743","volume":"7","author":"D\u2019Incalci","year":"2002","journal-title":"Oncologist"},{"issue":"41","key":"10.1016\/j.ejca.2011.01.016_b0035","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejca.2011.01.016_b0040","first-page":"179","article-title":"Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.ejca.2011.01.016_b0045","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1073\/pnas.97.12.6780","article-title":"Interference of transcriptional activation by the anti-neoplastic drug ET-743","volume":"97","author":"Minuzzo","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2011.01.016_b0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","article-title":"Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways","volume":"92","author":"Damia","year":"2001","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2011.01.016_b0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin-743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2011.01.016_b0060","first-page":"4899","article-title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells","volume":"62","author":"Furuta","year":"2002","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2011.01.016_b0065","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-07-2432","article-title":"Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin","volume":"7","author":"Casado","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.01.016_b0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression free rate as the principal end-point for Phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.01.016_b0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0002-9440(10)63985-5","article-title":"Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue","volume":"158","author":"Specht","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2011.01.016_b0080","unstructured":"Ladanyi M, Antonescu CR, Dal Cin P. Cytogenetic and molecular genetic pathology of sotf tissue tumors. In: Sharon W. Weiss, John R. Goldblum (Eds.) Soft Tissue Tumors, Mosby Elsevier 2008, chapter 4:73\u2013102."},{"key":"10.1016\/j.ejca.2011.01.016_b0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/jm010370d","article-title":"A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions","volume":"45","author":"Marco","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2011.01.016_b0090","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/jm990241l","article-title":"Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove","volume":"42","author":"Zewail-Foote","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2011.01.016_b0095","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chembiol.2005.08.009","article-title":"DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin","volume":"12","author":"David-Cordonnier","year":"2005","journal-title":"Chem Biol"},{"issue":"16","key":"10.1016\/j.ejca.2011.01.016_b0100","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","article-title":"Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin","volume":"66","author":"Herrero","year":"2006","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2011.01.016_b0105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1074-5521(01)00071-0","article-title":"The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent","volume":"8","author":"Zewail-Foote","year":"2001","journal-title":"Chem Biol"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.016_b0110","first-page":"185","article-title":"Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.016_b0115","doi-asserted-by":"crossref","unstructured":"Takebayashi Y, Pourquier P, Yoshida A, Kohlhagen G, Pommier Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci USA Jun 22;USA 1999;96(13):7196\u2013201.","DOI":"10.1073\/pnas.96.13.7196"},{"issue":"7","key":"10.1016\/j.ejca.2011.01.016_b0120","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall-cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.016_b0125","doi-asserted-by":"crossref","first-page":"4215s","DOI":"10.1158\/1078-0432.CCR-040006","article-title":"Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ejca.2011.01.016_b0130","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non\u2013small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.01.016_b0135","doi-asserted-by":"crossref","unstructured":"Boukovinas I, Papadaki C, Mendez P et al. Tumor BRCA1, RRM1 and RRM2 mRNA Expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008;3(11):e3695. doi:10.1371\/journal.pone.0003695.","DOI":"10.1371\/journal.pone.0003695"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T21:21:05Z","timestamp":1560028865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0959804911000438"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.01.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}